SOMCL-085, a novel multi-targeted FGFR inhibitor,displays potent anticancer activity in FGFR-addicted human cancer models

导出原文传递学术成果认领

作者单位 Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai 200032, China ^[1] Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China ^[2] CAS Key Laboratory of Receptor Research, and Synthetic Organic & Medicinal Chemistry Laboratory(SOMCL), Shanghai Institute of Materia Medica,Chinese Academy of Sciences, Shanghai 201203, China ^[3]

关键词 human cancer anticancer drug SOMCL-085 receptor tyrosine kinase FGFR xenograft nude mouse model

栏目名称 Chemotherapy

DOI 10.1038/aps.2017.96

发布时间 2018-03-26

基金项目

funds from the National Natural Science Foundation of China grants from the Science and Technology Commission of Shanghai Municipality grants from the "Personalized Medicines-Molecular Signature-based Drug Discovery and Development",Strategic Priority Research Program of the Chinese Academy of Sciences

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0
被引3
下载0

中国药理学报（英文版）

2018年39卷2期

243-250页

SCIMEDLINEISTICCSCDCABP

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

SOMCL-085, a novel multi-targeted FGFR inhibitor,displays potent anticancer activity in FGFR-addicted human cancer models

中国药理学报（英文版）

相似文献

中国药理学报（英文版）

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

SOMCL-085, a novel multi-targeted FGFR inhibitor,displays potent anticancer activity in FGFR-addicted human cancer models

中国药理学报（英文版）

相似文献

中国药理学报（英文版）

相关期刊

检索历史清除